AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) - Trial NCT00638612
Access comprehensive clinical trial information for NCT00638612 through Pure Global AI's free database. This Phase 1 trial is sponsored by Candel Therapeutics, Inc. and is currently Completed. The study focuses on Pancreatic Adenocarcinoma,Pancreatic Cancer. Target enrollment is 27 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Candel Therapeutics, Inc.
Timeline & Enrollment
Phase 1
Aug 01, 2008
Jun 01, 2015
Primary Outcome
Incidence of treatment emergent adverse events
Summary
The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene
 Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral
 vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk),
 followed by an antiherpetic prodrug, valacyclovir.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00638612
Non-Device Trial